A phase 2 trial has been conducted to evaluate the efficacy and safety of nipocalimab in patients with moderate-to-severe Sjögren's disease. The trial results suggest that nipocalimab may improve disease activity and reduce symptoms such as pain and dryness, particularly in patients with high autoantibody levels. However, the overall efficacy of nipocalimab in treating Sjögren's disease is still being assessed, with mixed results reported in various studies.